Future Program: Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID)

The Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) program aims to develop a shelf-stable, blood analog system that can be manufactured at scale. The program will focus on biosynthetic, blood analog components paired with durable, field-ready delivery systems, rapid point-of-care diagnostic tools, and clinical guidelines needed for their use. The program is divided into two phases: Phase 1 (12 months) will focus on demonstrating the viability of individual components and their compatibility with each other, while Phase 2 (24 months) will focus on final preclinical development, clinical development, regulatory strategy execution, manufacturing scale up, and product commercialization. Some key points to consider: • The program seeks to deliver a shelf-stable, blood analog system authorized within the next three years. • The system should include blood analog components such as oxygen carriers, plasma, and platelets or platelet-like particles. • The program will focus on manufacturing at scale, product commercialization, and the development of a regulatory pathway for individual and combined products. • The capabilities generated in this program will have the ability to save the lives of warfighters and civilians.